When Donald Trump returned to the White House in January 2025, the question wasn't whether his administration would change the direction of US health policy – it was how quickly, how deeply
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.